Nasopharyngeal protein biomarkers of acute respiratory virus infection and methods of using same
AssigneeDuke University
InventorsThomas W. Burke, Ricardo Henao Giraldo, Erik Soderblom, Joseph Lucas, Christopher W. Woods, Geoffrey S. Ginsburg
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods for determining the presence or absence of and/or the etiology of an acute respiratory viral infection in a subject, as well as methods of treating the subject based on the determination, by measuring on a platform the expression levels of a pre-defined set of gene products.
Claims20
A method of treating a subject having an acute respiratory viral (ARV) illness, wherein the ARV illness is caused by an influenza pathogen, said method comprising:
- (1) determining an etiology of the illness comprising:
- (a) obtaining a biological sample from the nasopharyngeal space or endotracheal site of the subject;
- (b) measuring on a platform expression levels of pre-determined set of proteins and/or peptides for the platform in said biological sample, wherein the pre-determined set of proteins and/or peptides comprises form 9 to 26 proteins and/or component peptides/epitopes listed in Table 2/2A or Table S4 , and comprises A1AG1, TIG1, ANXA2, LCN15, ANGT, CFAB, TBA1B, CAYP1 and STAT, and wherein the measuring comprises detection and quantification of the proteins and/or component peptides/epitopes;
- (c) normalizing the expression levels to generate normalized expression values;
- (d) entering the normalized expression values into one or more acute respiratory virus (ARV) illness classifiers, said classifier(s) comprising pre-defined weighting values for each of the proteins and/or peptides for the platform;
- and
- (e) calculating an etiology probability for the ARV illness based upon said normalized expression values and said classifier(s),
- wherein said subject is determined to have the ARV illness;
- and
- (2) administering to the subject an appropriate treatment regimen,
- wherein said appropriate treatment regimen comprises an antiviral therapy.
A method of treating a subject having an acute respiratory viral (ARV) illness, wherein the ARV illness is caused by a human rhinovirus (HRV) pathogen, said method comprising:
- (1) determining an etiology of the illness comprising:
- (a) obtaining a biological sample from the nasopharyngeal space or endotracheal site of the subject;
- (b) measuring on a platform expression levels of a pre-determined set of proteins and/or peptides for the platform in said biological sample, wherein the pre-determined set of proteins and/or peptides comprises from 9to 26proteins and/or component peptides/epitopes listed in Table 2/2A or Table S4, and comprises A1AG1, TIG 1, ANXA2, LCN15, ANGT, CFAB, TBA1B, CAYP1, and STAT, and wherein the measuring comprises detection and quantification of the proteins and/or component peptides/epitopes;
- (c) normalizing the expression levels to generate normalized expression values;
- (d) entering the normalized expression values into one or more ARV illness classifiers, said classifier(s) comprising pre-defined weighting values for each of the proteins and/or peptides for the platform;
- and
- (e) calculating an etiology probability for the ARV illness based upon said normalized expression values and said classifier(s),
- wherein said subject is determined to have the ARV illness;
- and
- (2) administering to the subject an appropriate treatment regimen,
- wherein said appropriate treatment regimen comprises one or more therapeutic agents capable of producing a reduction of symptoms associated with the ARV illness.
Dependencies are inferred from the claim text.